Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Danish severe asthma register: an electronic platform for severe asthma management and research

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Hansen, Susanne ; Hilberg, Ole ; Ulrik, Charlotte Suppli ; Bodtger, Uffe ; M Rasmussen, Linda ; D Assing, Karin ; Wimmer-Aune, Alexandra ; B Rasmussen, Kirsten ; Bjerring, Niels ; Christiansen, Anders ; Schmid, Johannes ; Krogh, Niels Steen ; Porsbjerg, Celeste. / The Danish severe asthma register : an electronic platform for severe asthma management and research. In: European Clinical Respiratory Journal. 2021 ; Vol. 8, No. 1. pp. 1-13.

Bibtex

@article{4ae160df21b040daa51b4cd924311545,
title = "The Danish severe asthma register: an electronic platform for severe asthma management and research",
abstract = "The evaluation and management of severe asthma patients require collection of comprehensive information, which is often a challenge in a busy outpatient clinic. The Danish Severe Asthma Register (DSAR) was designed as an electronic patient record form that captures operational clinical data and provides a clinical overview of the severe asthma patient. DSAR is a nationwide register; all patients in Denmark who are treated with biologics for severe asthma are included, and data are as a minimum entered at start of biological treatment, after four and 12 months of treatment, and hereafter annually. Currently, there are data from 621 treatment courses with biologics included in DSAR, with 71% of patients treated with anti-IL-5 drugs and 29% with an anti-IgE drug. Patients enter Patient Reported Outcome Measures electronically on tablets when they arrive in the outpatient clinic and their answers are immediately available to the clinician during the consultation. Nurses and doctors enter clinical data into DSAR during the consultation. DSAR offers immediate access to well-presented longitudinal overview and automatically creates a journal output that can be copy-pasted into the hospital's existing health record form. DSAR is also currently expanding with an app, to be used for monitoring of home-treatment. In addition to serving as an electronic patient record form, DSAR will also provide opportunities to monitor the real-life efficacy of biological treatment for severe asthma in Denmark, and it will be a valuable research platform that will aid in answering important research questions on severe asthma in the future.",
keywords = "Severe asthma, biological treatment, clinical decision-making tool, electronic patient record, real-life efficacy, severe asthma research",
author = "Susanne Hansen and Ole Hilberg and Ulrik, {Charlotte Suppli} and Uffe Bodtger and {M Rasmussen}, Linda and {D Assing}, Karin and Alexandra Wimmer-Aune and {B Rasmussen}, Kirsten and Niels Bjerring and Anders Christiansen and Johannes Schmid and Krogh, {Niels Steen} and Celeste Porsbjerg",
note = "{\textcopyright} 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2021",
doi = "10.1080/20018525.2020.1842117",
language = "English",
volume = "8",
pages = "1--13",
journal = "European Clinical Respiratory Journal",
issn = "2001-8525",
publisher = "Co-Action Publishing",
number = "1",

}

RIS

TY - JOUR

T1 - The Danish severe asthma register

T2 - an electronic platform for severe asthma management and research

AU - Hansen, Susanne

AU - Hilberg, Ole

AU - Ulrik, Charlotte Suppli

AU - Bodtger, Uffe

AU - M Rasmussen, Linda

AU - D Assing, Karin

AU - Wimmer-Aune, Alexandra

AU - B Rasmussen, Kirsten

AU - Bjerring, Niels

AU - Christiansen, Anders

AU - Schmid, Johannes

AU - Krogh, Niels Steen

AU - Porsbjerg, Celeste

N1 - © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2021

Y1 - 2021

N2 - The evaluation and management of severe asthma patients require collection of comprehensive information, which is often a challenge in a busy outpatient clinic. The Danish Severe Asthma Register (DSAR) was designed as an electronic patient record form that captures operational clinical data and provides a clinical overview of the severe asthma patient. DSAR is a nationwide register; all patients in Denmark who are treated with biologics for severe asthma are included, and data are as a minimum entered at start of biological treatment, after four and 12 months of treatment, and hereafter annually. Currently, there are data from 621 treatment courses with biologics included in DSAR, with 71% of patients treated with anti-IL-5 drugs and 29% with an anti-IgE drug. Patients enter Patient Reported Outcome Measures electronically on tablets when they arrive in the outpatient clinic and their answers are immediately available to the clinician during the consultation. Nurses and doctors enter clinical data into DSAR during the consultation. DSAR offers immediate access to well-presented longitudinal overview and automatically creates a journal output that can be copy-pasted into the hospital's existing health record form. DSAR is also currently expanding with an app, to be used for monitoring of home-treatment. In addition to serving as an electronic patient record form, DSAR will also provide opportunities to monitor the real-life efficacy of biological treatment for severe asthma in Denmark, and it will be a valuable research platform that will aid in answering important research questions on severe asthma in the future.

AB - The evaluation and management of severe asthma patients require collection of comprehensive information, which is often a challenge in a busy outpatient clinic. The Danish Severe Asthma Register (DSAR) was designed as an electronic patient record form that captures operational clinical data and provides a clinical overview of the severe asthma patient. DSAR is a nationwide register; all patients in Denmark who are treated with biologics for severe asthma are included, and data are as a minimum entered at start of biological treatment, after four and 12 months of treatment, and hereafter annually. Currently, there are data from 621 treatment courses with biologics included in DSAR, with 71% of patients treated with anti-IL-5 drugs and 29% with an anti-IgE drug. Patients enter Patient Reported Outcome Measures electronically on tablets when they arrive in the outpatient clinic and their answers are immediately available to the clinician during the consultation. Nurses and doctors enter clinical data into DSAR during the consultation. DSAR offers immediate access to well-presented longitudinal overview and automatically creates a journal output that can be copy-pasted into the hospital's existing health record form. DSAR is also currently expanding with an app, to be used for monitoring of home-treatment. In addition to serving as an electronic patient record form, DSAR will also provide opportunities to monitor the real-life efficacy of biological treatment for severe asthma in Denmark, and it will be a valuable research platform that will aid in answering important research questions on severe asthma in the future.

KW - Severe asthma

KW - biological treatment

KW - clinical decision-making tool

KW - electronic patient record

KW - real-life efficacy

KW - severe asthma research

UR - http://www.scopus.com/inward/record.url?scp=85094957077&partnerID=8YFLogxK

U2 - 10.1080/20018525.2020.1842117

DO - 10.1080/20018525.2020.1842117

M3 - Journal article

C2 - 33209214

VL - 8

SP - 1

EP - 13

JO - European Clinical Respiratory Journal

JF - European Clinical Respiratory Journal

SN - 2001-8525

IS - 1

M1 - 1842117

ER -

ID: 61308276